-+ 0.00%
-+ 0.00%
-+ 0.00%

Parabilis Medicines Initiates Dose-Ranging Clinical Cohort Evaluating Zolucatetide In Patients With Familial Adenomatous Polyposis As Part Of Ongoing Phase 1/2 Clinical Trial

Benzinga·10/14/2026 11:05:29
Listen to the news

New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors

Zolucatetide directly inhibits β-catenin:TCF, targeting the APC-mutation biology that drives precancerous adenomatous polyp formation in patients with FAP

CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (NASDAQ:PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the initiation of a dose-ranging clinical cohort evaluating zolucatetide in patients with familial adenomatous polyposis (FAP) as part of the company’s ongoing Phase 1/2 clinical trial. Zolucatetide is Parabilis’ lead investigational Helicon™ peptide and the first and only direct inhibitor of the β-catenin:TCF interaction, a key driver of a range of cancers and tumor types.